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The brain requires 20% of the body’s
total energy.When the body is deprived of
energy, such as during hypoxia and in pa-
thologies involving an altered energy me-
tabolism, the brain’s function can be
severely and irreversibly disrupted. How-
ever, humans routinely cope with tran-
sient hypoxia, for example when diving
under water. How do our brains resist this
temporary disruption in energy supply,
and is it possible to harness these mecha-
nisms for therapeutic use?
Much of the brain’s energy is spent
generating synaptic and action potentials
and subsequently re-establishing the rest-
ing membrane potential by powering the
Na/K-ATPase. To fuel these and other
processes, the brain generates ATP.Under
normoxic conditions, the predominant
sourceof energy is theoxidativemetabolism
of glucose. During hypoxia, intracellular
ATP levels fall and the Na/K-ATPase
slows down. As a consequence, ionic gradi-
ents decrease. Neurons become depolarized
and may either become more excitable or
enter a depolarizing block of action poten-
tial production. To prevent neuronal dam-
age by depolarization-evoked calcium
entry, adenosine is released into the extra-
cellular space, which in turn suppresses glu-
tamate release from presynaptic terminals,
reducing synaptic activity (Fowler, 1993).
Brief hypoxia or even anoxia and the result-
ing adenosine release are reversible and do
not lead to neuronal cell death (Miyamoto
and Auer, 2000). However, the external K
concentration jumps to50mM after a few
minutes of anoxia, leading to a rapid depo-
larization of cellular membranes, the so-
called “anoxic depolarization” (Hansen,
1985). A prolonged rise of extracellular
glutamate concentration then triggers
widespread neuronal cell death, after
which anoxic damage becomes irrevers-
ible, leading to severe neuropsychologi-
cal impairments.
Importantly, several reserve energy
substrates can be used to replenish ATP
without aneed for oxygen, thusdelaying the
anoxia-induced alteration of ion gradients.
In addition to glycogen, creatine is used as
such an energy buffer in the brain. Creatine
kinase catalyzes the dephosphorylation of
phosphocreatine and the simultaneous
phosphorylation of adenosine diphosphate
(ADP) to ATP in the following reaction:
PCrADPH7CrATP.
Physiological creatine and creatine ki-
nase concentrations are not homoge-
neous throughout the brain, but instead
reflect regional differences in energy de-
mands (Pouwels and Frahm, 1998); in-
deed, creatine kinase level correlates with
brain activity asmeasuredwith EEG (Sau-
ter and Rudin, 1993). Furthermore, both
in vitro and behavioral evidence suggest
that creatine is used as an emergency en-
ergy substrate, at least for a short time.
Rodent hippocampal slices with fourfold
enriched phosphocreatine levels retain
synaptic transmission in hypoxia three
times as long as without extra phospho-
creatine, and ATP levels take 90 instead of
30 s to decline (Lipton andWhittingham,
1982). While remaining constant at rest,
the ratio of hippocampal phosphocre-
atine to ATP concentration declines
significantly when glucose uptake is im-
paired under cognitive load, suggesting
that phosphocreatine is converted to cre-
atine to replenish ATP (Emmanuel et al.,
2013).
Can artificially increasing phosphocre-
atine levels help conserve neuronal func-
tion in disorders of energy supply? Studies
of the clinical benefits of creatine admin-
istration have been contradictory. In a
mouse model of amyotrophic lateral scle-
rosis (ALS), a disease characterized in part
by mitochondrial dysfunction and there-
fore impaired energy supply, oral creatine
supplementation protected against neu-
ronal loss and improved motor perfor-
mance. Crucially, it also led to longer
survival rates, from 144 d with an un-
supplemented diet to 157 d with 1% crea-
tine and 169 d with 2% creatine (Klivenyi
et al., 1999). Klivenyi et al. (1999) hypoth-
esized that creatine both acted as an
energy buffer and prevented the mito-
chondrial transition pore from opening
(O’Gorman et al., 1997), thereby prevent-
ing the mitochondrial swelling and cell
death characteristic of ALS. In contrast, a
comparable dose of creatine in ALS pa-
tients failed to improve motor behavior
(Shefner et al., 2004). Similarly, in pa-
tients with Huntington’s disease, which
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involves a defective energy metabolism
and excitotoxicity, 2-year oral supple-
mentation of creatine did not improve
motor or cognitive function (Tabrizi et
al., 2005).
Turner and colleagues (2015) tried to
address these discrepancies by investigat-
ing whether prophylactic oral creatine in-
take prevented the detrimental effects of
hypoxia on cognitive performance in hu-
mans. The authors tested corticomotor
excitability by measuring motor-evoked
potentials with TMS and assessed cogni-
tive performance on a variety of tasks con-
tained in a standard neuropsychological
test battery under normoxic conditions
and after 90 min of hypoxia. Participants
(n  15) underwent the test procedure
twice. Seven days of placebo or oral crea-
tine administration (20 g/d), allocated ac-
cording to a double-blind randomized
procedure, were followed by a wash-out
period of 5 weeks, after which the proce-
dure was repeated with the other treat-
ment (creatine or placebo, respectively).
Using magnetic resonance spectroscopy,
the authors demonstrated that creatine
treatment increased creatine and phos-
phocreatine levels by 9.2% on average in a
region of interest over the hand motor
area, the same area used to determine cor-
ticomotor excitability.
Hypoxiawas induced by having partic-
ipants breathe air containing an inspired
oxygen fraction of 10%, or half the level in
air at sea level. The arterial oxygen satura-
tion fell by 19% as expected from the
oxygen-hemoglobin dissociation curve
(Turner et al., 2015, their Fig. 3), which is
well below the clinical threshold for hy-
poxemia (Majumdar et al., 2011). To put
that level of hypoxia into perspective, an
inspired oxygen fraction of 10% approxi-
mately corresponds to air at the summit of
Mount Whitney, at an altitude of around
4.4 km.
Hypoxia impaired a wide range of
neuropsychological measures, including
alertness, executive function, and verbal
memory. Creatine supplementation sig-
nificantly reduced the detrimental effects
of hypoxia on a factor the authors call
“complex attention” (Turner et al.,
2015,their Table 1 and Fig. 4). Turner and
colleagues (2015) assessed complex atten-
tion by pooling performance errors across
three cognitive tasks: a Stroop test, in
which subjects concurrently processed the
semantic and the visual features of a color
word; a Shifting Attention test, in which
subjects switched between task instruc-
tions; and a Continuous Performance
test, in which subjects responded to target,
but not distractor letters. The effect of crea-
tine on composite memory, psychomotor
speed, and the overall neurocognitive index
were statistically inconclusive, even though
all domains were adversely affected by hyp-
oxia. Given the heterogeneous distribution
of creatine in the brain, it is conceivable that
these differences in behavior reflect differ-
ences in creatine sensitivity across networks
engaged in these different tasks. Similarly,
the differences in cognitive effects for hyp-
oxia under placebo and under creatine
might indicate that hypoxia and creatine
differentially affect different cognitive
domains.
It is worth noting that the authors tested
participants on a battery comprising a large
number of neurocognitive tests. Testing for
independent effects would require correc-
tions for multiple comparisons, which
would have eliminated the statistically sig-
nificant effect of creatine supplementation.
However, in this case it is unlikely that all of
the neurocognitive tests are truly indepen-
dent. Several identical subscores were in-
cluded in different composite cognitive
domains scores, and different domains,
such as psychomotor speed and reaction
time, probably recruit similar cognitivepro-
cesses. In consequence, corrections for
multiple comparisons might be overly con-
servative. To tease apart the effects of crea-
tine on specific cognitive processes, future
studies using a similar cognitive test battery
could first perform a dimensionality reduc-
tion to clearly identify independent cogni-
tive domains.
Turner and colleagues (2015) hypoth-
esize that the effect of creatine on cogni-
tive performancemight, at least in part, be
due to creatine’s energy-buffering capa-
bilities. However, it is unlikely that crea-
tine can supply energy for the entire 90
min of hypoxia. In the absence of ATP
production, all the ATP in the rat brain
will be consumed in 7 s (Allen et al.,
2005). The concentration of free ATP in
the rodent and human brain is2.5 mM,
while the phosphocreatine concentration
is 4.9 mM (Roth and Weiner, 1991).
Thus, ATP produced from the physiolog-
ical level of phosphocreatine should be
able to lengthen the time until ATP is con-
sumed by12 s in rat (Allen et al., 2005),
or 24 s in humans and nonhuman pri-
mates [because primate gray matter con-
sumes only around half as much energy as
rodent gray matter, or 0.2 mM ATP per
second (Kennedy et al., 1978)]. Since the
increase of creatine and phosphocreatine
produced was 1 mM (as shown in
Turner et al. (2015), their Fig. 2A), any
energy-buffering effect of the extra crea-
tine must occur within a few seconds and
should therefore be restricted to the first
neuro-psychological test that participants
performed. As Turner and colleagues
(2015) do not indicate whether the order
of the tests was randomized, it is not clear
whether the selective effects of creatine on
complex attention might be explained by
it being the first test in the battery.
Any longer-lasting effect of creatine on
cognitive performance would instead
support the alternative hypothesis of
Turner and colleagues (2015) of a sub-
stantial neuromodulatory role of creatine,
possibly by directly enhancing the func-
tion of the Na/K-ATPase (Rambo et
al., 2012). Creatine also directly stimulates
glutamate uptake into synaptic vesicles
(Xu et al., 1996).
Superficially, one might expect an in-
crease of corticomotor excitability in
hypoxia, altering the cortical excitation/in-
hibition balance with potentially detrimen-
tal consequences for cognitiveperformance.
The neuromodulatory effects of creatine
might then reverse these effects. Instead,
Turner and colleagues (2015) saw no statis-
tically significant effect of hypoxia on excit-
ability in placebo, but an increased
excitability with creatine (their Fig. 5A).
However, the analyses in Figure 5 do not
allowadirect comparisonof changes in cor-
ticomotor excitability between placebo and
creatine, as the amplitudes were separately
normalized to the largestmotor-evokedpo-
tential recorded in the placebo and creatine
sessions, and so are not comparable across
conditions.
In comparison to clinical studies using a
similar dose of creatine that found no bene-
ficial effects on cognitive performance, a
crucial difference that could explain the ef-
ficacy of creatine supplementation in this
study is that creatine was allowed to accu-
mulate before energetic disruption. In the
clinical studies by Shefner and colleagues
(2004) and Tabrizi and colleagues (2005),
creatine treatment was only started after
ALSorHuntington’swere alreadymanifest.
In contrast, creatine supplementation pre-
ceded disease onset in the ALS mouse
model, where it was efficacious (Klivenyi et
al., 1999). If a beneficial effect of creatine is
successfully replicated, futureclinical imple-
mentationcould therefore focusonprophy-
lactic, rather thanpost hoc, effects of creatine
in the treatment of disorders involving
changes in energy metabolism.
In conclusion, Turner and colleagues
(2015) show that even relativelymild hyp-
oxia impairs cognition, which might, at
least in part, be recovered by oral creatine
supplementation. This suggests that crea-
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tine helps to maintain normal cognitive
function when energy metabolism is im-
paired, although the precise mechanism,
as well as the reason that some cognitive
processes are more affected than others,
remain unexplained. As the energy-
buffering effects of added creatine are of
brief duration (a few seconds), future
mechanistic studies should focus on the
neuromodulatory actions of creatine un-
der prolonged hypoxia.
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